These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 29341404)

  • 1. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.
    Yang M; Yue H; Xu Q; Shao S; Chen Y
    Diabetes Obes Metab; 2024 Aug; 26(8):3137-3146. PubMed ID: 38699792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
    Jazi M; Porfiris G
    Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
    Yabe D; Iwasaki M; Kuwata H; Haraguchi T; Hamamoto Y; Kurose T; Sumita K; Yamazato H; Kanada S; Seino Y
    Diabetes Obes Metab; 2017 May; 19(5):739-743. PubMed ID: 27990776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 9. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.
    Siebel S; Galderisi A; Patel NS; Carria LR; Tamborlane WV; Sherr JL
    Diabetes Technol Ther; 2019 Mar; 21(3):101-104. PubMed ID: 30688521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.
    Kutoh E; Hayashi J
    Drug Res (Stuttg); 2019 May; 69(5):297-300. PubMed ID: 30296805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
    Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
    Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
    Clement M; Senior P
    Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
    [No Abstract]   [Full Text] [Related]  

  • 13. Canagliflozin: A Review in Type 2 Diabetes.
    Deeks ED; Scheen AJ
    Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer.
    Sanyal D; Majumder A; Ghosh S; Pandit K
    Diabetes Metab Syndr; 2021; 15(1):385-389. PubMed ID: 33548908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
    Koch RA; Clark RF
    Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
    [No Abstract]   [Full Text] [Related]  

  • 19. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
    Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.